Neurology 909 - Neurology Alert - Sep 01, 2005

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editors
Fred Plum, MD
University Professor;
Department of Neurology;
Cornell University Medical College

M. Flint Beal, MD
Professor and Chairman
Department of Neurology
Cornell University Medical College
New York, NY

Associate Editor
John J. Caronna, MD
Vice-Chairman
Department of Neurology
Cornell University Medical Center
Professor of Clinical Neurology
New York-Presbyterian Hospital

Assistant Editors
Brian R. Apatoff, MD, PhD
Associate Professor of Neurology
New York Presbyterian Hospital- Cornell Campus

Steven Frucht, MD
Assistant Professor of Neurology
Movement Disorders Division
Columbia-Presbyterian Medical Center

Jeffrey Reich, MD
Assistant Professor of Neurology
New York Presbyterian Hospital
Cornell Campus

Norman R. Relkin, MD, PhD
Associate Professor
Clinical Neurology and Neuroscience
New York Presbyterian Hospital- Cornell Campus

Michael Rubin, MD
Professor of Clinical Neurology
New York-Presbyterian Hospital
Cornell Campus

Alan Z. Segal, MD
Assistant Professor
Department of Neurology
Weill-Cornell Medical College
Attending Neurologist
New York-Presbyterian Hospital

Author
Barry E. Kosofsky
Attending Pediatrician
New York Presbyterian Hospital
Professor
Cornell Medical College
Research Associate
Massachusetts General Hospital

Dana Leifer,MD
Associate Professor of Neurology
Weill Medical College of Cornell University

Subjects:

  • PML Complicating Treatment with Natalizumab (Tysabri) for MS
  • Review: Treatment of Inflammatory Neuropathies
  • Genetic Predictors of AED Dosing
  • Transient Ischemic Attack: Short-Term and Long-Term Risk Factor for Stroke
  • Fleur du Mal: IRIS in AIDS-Related PML
  • A New Cause of Treatment-Responsive Limbic Encephalitis

Objectives:

  • Present current scientific data regarding diagnosis and treatment of neurologic disease, including stroke, Alzheimer?s disease, transient ischemic attack, and coma
  • Discuss the pathogenesis and treatment of pain
  • Present "basic science? lessons in brain function
  • Discuss information regarding new drugs for commonly diagnosed diseases and new uses for traditional drugs
  • Discuss nonclinical issues of importance to neurologists, such as the right to die and the physician?s legal obligation to patients with terminal illness

Financial Disclosure:

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Assistant Editor Brian R. Apatoff, MD, PhD is on the speaker’s bureau of Biogen and Teva.



Assistant Editor Norman R. Relkin, MD, PhD is on the speaker’s bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.

Assistant Editor Michael Rubin, MD is on the speaker’s bureau for Athena Diagnostics and does research for Viatris.

Assistant Editor Alan Z. Segal, MD is on the speaker’s bureau of Boehringer-Ingelheim.

Editors Fred Plum, MD and M. Flint Beal, MD, Associate Editor John J. Caronna, MD, Assistant Editors Steven Frucht, MD, and Jeffrey Reich, MD, and Authors Dana Leifer,MD and Barry E. Kosofsky report no consultant, stockholder, speaker’s bureau, research, or other relationships related to this field of study.

Copyright 2005 AHC Media. All rights reserved.